{"id":"W4210686684","doi":"10.3324/haematol.2021.279520","title":"Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; BC Children's Hospital; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Children's Hospital of Philadelphia; U.S. Department of Defense; Rally Foundation; V Foundation for Cancer Research","keywords":"Medicine; Temsirolimus; Etoposide; Mucositis; Internal medicine; Gastroenterology; Cyclophosphamide; Leukemia; Leukopenia; Pharmacology; PI3K/AKT/mTOR pathway; Toxicity; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005234628,0.0006203952,0.001358255,0.0004572349,0.0006158408,0.00005117384,0.0003902,0.0002588924,0.000131086],"category_scores_gemma":[0.0003086773,0.000425451,0.000120791,0.0007421233,0.0003973951,0.0002808066,0.000280931,0.00108241,0.00001959429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002470777,"about_ca_system_score_gemma":0.002680524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007705652,"about_ca_topic_score_gemma":0.000049358,"domain_scores_codex":[0.9956391,0.0003718256,0.0008436239,0.0009959437,0.001075679,0.0010738],"domain_scores_gemma":[0.9966176,0.001669918,0.0005009312,0.0006468756,0.0002073748,0.0003572624],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6729771,0.006882448,0.3006238,0.001465456,0.001166636,0.003242858,0.001600953,0.00112949,0.0001099048,0.001172314,0.004431162,0.005197927],"study_design_scores_gemma":[0.6743637,0.07260521,0.2366204,0.000262456,0.00212649,0.001998698,0.001058748,0.001528861,0.0002168377,0.001210606,0.00627186,0.001736174],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915053,0.002107867,0.0001785349,0.0001867646,0.0002483028,0.005024519,0.000127594,0.0001843357,0.0004367434],"genre_scores_gemma":[0.9950565,0.0006550245,0.0006745888,0.0007194706,0.0001010331,0.002167189,0.0002488265,0.0001185924,0.0002588369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06572276,"threshold_uncertainty_score":0.9998198,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007659484694420746,"score_gpt":0.2440506352102129,"score_spread":0.2363911505157922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}